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Rational design of iridium–porphyrin conjugates
for novel synergistic photodynamic and
photothermal therapy anticancer agents†
Liping Zhang,‡a Yun Geng, ‡a Lijuan Li,a Xiaofan Tong,a Shi Liu, b Xingman Liu,a
Zhongmin Su, a Zhigang Xie, *b Dongxia Zhu *a and Martin R. Bryce *c
Near-infrared (NIR) emitters are important probes for biomedical applications. Nanoparticles (NPs)
incorporating mono- and tetranuclear iridium(III) complexes attached to a porphyrin core have been
synthesized. They possess deep-red absorbance, long-wavelength excitation (635 nm) and NIR emission
(720 nm). TD-DFT calculations demonstrate that the iridium–porphyrin conjugates herein combine the
respective advantages of small organic molecules and transition metal complexes as photosensitizers
(PSs): (i) the conjugates retain the long-wavelength excitation and NIR emission of porphyrin itself; (ii) the
conjugates possess highly effective intersystem crossing (ISC) to obtain a considerably more long-lived
triplet photoexcited state. These photoexcited states do not have the usual radiative behavior of
phosphorescent Ir(III) complexes, and they play a very important role in promoting the singlet oxygen
(1O2) and heat generation required for photodynamic therapy (PDT) and photothermal therapy (PTT). The
tetranuclear 4-Ir NPs exhibit high 1O2 generation ability, outstanding photothermal conversion efficiency
(49.5%), good biocompatibility, low half-maximal inhibitory concentration (IC50) (0.057 mM), excellent
photothermal imaging and synergistic PDT and PTT under 635 nm laser irradiation. To our knowledge
this is the first example of iridium–porphyrin conjugates as PSs for photothermal imaging-guided
synergistic PDT and PTT treatment in vivo.
Introduction
Transition metal complexes have made remarkable achieve-
ments in the clinical treatment of neuropathy, tumor therapy
and diabetes.1 Phosphorescent iridium(III) complexes are espe-
cially attracting attention as photosensitizers (PSs) for photo-
therapy, owing to the excellent photothermal stability and high
intersystem crossing (ISC) ability.2–8 Unfortunately, the
currently reported PSs based on Ir(III) complexes are far from
ideal, and suffer from some obvious drawbacks: (1) the inherent
short excitation wavelength (ca. 450 nm) leads to auto-
uorescence interference, poor tissue penetration and a lack of
selective uptake by neoplastic tissue;9–13 (2) their applications
have mainly focused on photodynamic therapy (PDT), and
consequently their therapeutic effect is highly subject to the
oxygen content in the tumor, and tumor hypoxia limits the
formation of reactive oxygen species (ROS) which ultimately
leads to cancer cell death;14,15 (3) there are very few reports on
their application in photothermal therapy (PTT), which seri-
ously limits their applications in phototherapy.16–18 Therefore,
there is an urgent need to design Ir(III) complexes as PSs that
can overcome the above shortcomings and can achieve more
optimal tumor therapies.
PSs with long-wavelength excitation and deeper tissue
penetration are crucial to guarantee effective clinical applica-
tions.19,20 Studies have sought to extend the phototherapeutic
window by introducing uorescent groups into Ir(III) complexes,
such as boron dipyrromethene (BODIPY)21 and coumarin.22,23
This strategy merges the advantages of Ir(III) complexes with
long-lived triplet metal–ligand charge transfer (3MLCT) states
and uorescent molecular p–p* transitions, leading to prom-
ising anticancer activity.12 Most of these reported PSs require
excitation with short-wavelength light, which is ineffective for
deep tumors.3,4,24 PTT is usually triggered by red light and the
absorbed light energy can be converted into heat, which
provides a thermal effect leading to the apoptosis of cancer
cells.25–29 More importantly, PTT is independent of the oxygen
concentration, and is thus an excellent candidate to treat
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hypoxic tumors, which will effectively make up for the de-
ciency of PDT. However, few research works have studied Ir(III)
complexes as PSs for PTT, which is likely due to their short
excitation wavelength (ca. 450 nm) caused by the typical 3MLCT
process. Additionally, the photothermal effect is benecial to
promote the internalization of PSs and oxygen in the tumor
tissues, thereby further improving the PDT effect.30–33 Hence,
synergistic PDT and PTT treatment is a more effective prospect
for tumor therapy in terms of concurrent metastasis than single
PDT or PTT.34–40 Therefore, achieving long-wavelength excita-
tion of PSs is a very important goal to realize PTT and to effec-
tively overcome the oxygen dependence in PDT, and ultimately
to improve the clinical outcome of phototherapy.
Porphyrin derivatives have been utilized as phototherapy
reagents due to their absorption in the red-light region,
although this absorption is of relatively low intensity.41 Specic
varied examples include tetraphenylchlorin as a photosensi-
tizer, a phosphatidylcholine-pyropheophorbide conjugate,
a diphenylporphyrin conjugated polymer and a chlorin-based
porous organic polymer.42–46 However, they possess the
common drawbacks of the small organic molecular PSs, such as
larger energy gap (DEST) between the rst singlet excited state
(S1) and triplet state (T1) and less triplet photoexcited state
compared with transition metal complexes, which directly leads
to reduced 1O2 production and low photothermal conversion
efficiency.46–50 We asked the following question: Is it possible to
combine the respective advantages of small organic molecules
and transition metal complex PSs to obtain Ir(III)-porphyrin
conjugates with long-wavelength excitation for high-efficiency
synergistic PDT and PTT treatment?
We recently reported that multinuclear Ir(III) complexes
encapsulated in nanoparticles (NPs) have good biocompati-
bility, and that they can increase 3MLCT transitions and molar
absorption coefficients, resulting in excellent PDT effects.51
However, their short excitation wavelength (450 nm) is unsat-
isfactory for in vivo treatment due to poor tissue penetration. We
hypothesized that combining the advantages of long-
wavelength excitation and NIR emission of porphyrin itself,
and highly effective long-lived triplet photoexcited state of
transition metal complexes, inhibiting the phosphorescent
emission from transition metal complexes simultaneously,
would be a good strategy to enhance the photosensitizer-
assisted (PS-assisted) phototherapy, PDT and PTT.
Results and discussion
Recent promising metal–porphyrin conjugates include:
porphyrinoid-Pt(II) conjugates;52 metal–organic frameworks
with porphyrin ligands;53 a porphyrin–Ru complex conjugate;54
and a combination of cationic Cu–porphyrin with Schiff base
Cu complexes.55 These covalent porphyrin-transition metal
conjugates, used for PDT only, are structurally very different
from the molecules reported herein for PDT and PTT. In this
work, we synthesized two porphyrin derivatives substituted with
mono- and tetra-Ir(III) complexes, named 1-Ir and 4-Ir, respec-
tively (Fig. 1A), both of which can be excited with long-
wavelength light, and their corresponding polymer-
encapsulated NPs, named 1-Ir NPs and 4-Ir NPs. The iridium
complexes have a stereogenic metal center and will exist as
a mixture of L and D enantiomers. Separation of the enantio-
mers of an Ir complex is rarely accomplished and is beyond the
scope of the present work.56 Tetraphenylporphyrin (TPP),
a standard PS,42–46 is studied as a comparison to 1-Ir and 4-Ir.
The detailed synthetic procedures and spectroscopic charac-
terization of TPP, 1-Ir and 4-Ir are reported in the ESI (Fig. S1–
S13†). The 4-Ir molecule has a smaller DEST and stronger spin–
orbit couplings compared with TPP and 1-Ir, thereby signi-
cantly promoting the generation of abundant and effective
triplet photoexcited state through intersystem crossing. 4-Ir NPs
possess deep-red absorption, long-wavelength excitation (635
nm), near-infrared (NIR) emission, high 1O2 generation ability,
outstanding photothermal conversion efficiency (49.5%) and
good biocompatibility. More importantly, the temperature of
tumors injected with 4-Ir NPs could reach to 61.9 C aer laser
irradiation, and good photothermal imaging has been accom-
plished. The synergistic PDT and PTT effect of 4-Ir NPs gives
high-efficiency inhibition of tumor growth in vivo.
To study the molecular properties of TPP, L4, 1-Ir, and 4-Ir,
density functional theory (DFT) and time-dependent (TD-DFT)
calculations were performed in Gaussian 16. As shown in
Fig. S14,† the HOMO and LUMO of TPP and L4 with a large
overlap are delocalized on the p-conjugated porphyrin ring. On
the contrary, 1-Ir and 4-Ir exhibit obvious HOMO–LUMO sepa-
ration. The HOMO–LUMO energy gap decreases with the
increasing number of Ir centers from TPP (2.72 eV) to 4-Ir (2.31
eV). The calculations show that both the HOMO and LUMO
energy levels of L4 are raised somewhat compared to TPP
(Fig. S14†). However, the energy gap of L4 (2.63 eV) is changed
little compared with TPP (2.72 eV) and its energy gap is still
signicantly larger than that of Ir-4 (2.26 eV) (Fig. S14†). The
relatively narrow gap suggests a long-wavelength absorption,
especially for 4-Ir, which is promising for phototherapy. The
attached Ir complexes lled the missing excited states of the
porphyrin and did not affect the distribution of the excited
states of the porphyrin itself (Fig. 1B). As shown in Fig. 1C, the
strong absorptions in the long-wavelength region correspond-
ing to singlet excited states S5 and S9, which are close to the
absorptions of TPP, are derived from contributions of the
porphyrin unit. The lowest triplet excited state (T1) was mainly
contributed by the local charge-transfer transition in the
ligands (3LC) of one cyclometalated Ir complex. The absence of
orbital participation from the Ir atoms indicates that there is no
phosphorescent emission in 4-Ir. This means that 4-Ir complex
still retains long-wavelength excitation and near-infrared
emission originating from porphyrin, while a more long-lived
triplet photoexcited state is generated from the cyclometalated
Ir(III) fragments. Thereby, the participation of the cyclo-
metalated Ir(III) complexes at the singlet (Sn) and triplet (Tn)
excited states is benecial to the inter-system crossing (ISC) of 4-
Ir. The energy gap between S1 and T1 is reduced from TPP (0.79
eV) to 4-Ir (0.56 eV) as shown in Fig. 1B. At the same time, the
singlet and triplet photoexcited state with close energy levels
also increased along with the additional number of Ir centers
(Fig. 1B). The emission and transient decay of 4-Ir are shown in
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 5918–5925 | 5919
































































































Fig. S22.† The short excited-state lifetime (s 4.76 ns) indicates
that the uorescence of 4-Ir is from the porphyrin unit and not
from the attached Ir complexes.
Due to the large molecular size of 4-Ir, we take the spin–orbit
coupling values of TPP and 1-Ir as examples to nd the contri-
bution of the attached Ir complexes in increasing the ISC ability.
Compared with TPP, the spin–orbit coupling constants between
Sn and Tn of 1-Ir complex increased considerably from 0.297 to
148 cm1, as shown in Table S1.† These data indicate that the
spin–orbit coupling values in 4-Ir should be enhanced to an
even greater extent. Meanwhile, a comparison of the geomet-
rical structures at S0 and T1 states for TPP and 4-Ir, together with
their respective root mean square deviation (RMSD) (0.16 Å and
0.46 Å) suggests a larger nonradiative vibrational relaxation of 4-
Ir, as shown in Fig. S16.† The results indicate that the attached
cyclometalated Ir complexes without phosphorescent emission
play very important roles in: (i) greatly improving the highly
effective ISC ability to ensure sufficient triplet photoexcited
states; (ii) greatly promoting the nonradiative vibrational
processes for the energy conversion. Therefore, theoretical
results support our proposed design concept: namely, to realize
an advantageous combination of the photophysical perfor-
mance of porphyrin and iridium complexes.
The TPP NPs, 1-Ir NPs and 4-Ir NPs were prepared by
polymer-encapsulation (Fig. 2A).57–62 The introduced amphi-
philic polymer chain (DSPE-PEG-MAL) was used to obviously
change the biocompatibility of the compound.51,57 HIV-1 Tat as
the cell penetrating peptide can effectively promote the entry of
NPs into cells.51,57 Transmission electron microscopy (TEM)
images conrmed that TPP NPs, 1-Ir NPs and 4-Ir NPs exhibit
spherical morphologies with average diameters of about 44, 48,
57 nm, respectively (Fig. 2B). Similar features were observed in
Fig. 1 (A) Chemical structures of TPP, 1-Ir and 4-Ir; (B) the calculated excitation energy distributions of singlet (Sn) and triplet (Tn) excited states
for TPP, L4, 1-Ir and 4-Ir; (C) the transition charge density differences (CDD) for singlet (Sn) and triplet (Tn) excited states in 4-Ir; (D) the pho-
tophysical mechanism for photoactive cancer therapy using PSs; (E) schematic illustration of PSs for in vivo photophysical applications.
5920 | Chem. Sci., 2021, 12, 5918–5925 © 2021 The Author(s). Published by the Royal Society of Chemistry
































































































the scanning electron microscopy (SEM) images (Fig. S17†). The
hydrodynamic diameters of TPP NPs, 1-Ir NPs and 4-Ir NPs
determined by dynamic light scattering (DLS) are 74, 79 and
95 nm, respectively (Fig. S18; Table S3†). The larger sizes
measured by DLS than by TEM can be attributed to a hydrated
layer on the NPs. In addition, the zeta potential of the 4-Ir NPs
was determined to be +27.8 mV, conrming that HIV-1 Tat was
successfully conjugated to the surface of NPs.61,62 4-Ir NPs
released a low amount of 4-Ir (z1.69%) over 72 h in water
(Fig. S19†). Such a low release of contents veries that the PSs
remain intact as the active species. Moreover, no obvious
changes of the size or size distribution of TPP NPs, 1-Ir NPs and
4-Ir NPs were observed within 14 days suggesting the high
stability of the NPs. In addition, the size of 4-Ir NPs in serum
(118 nm) and PBS (106 nm) is stable within 14 days (Fig. S24†).
These NPs with spherical morphology, appropriate size and
excellent stability are suited for biological applications.
The UV-vis absorption and photoluminescence (PL) spectra
of TPP NPs, 1-Ir NPs and 4-Ir NPs were recorded in water. The
extended absorption band in the 500–700 nm region (Fig. 2C) is
advantageous for matching long-wavelength excitation to
enhance tissue penetration. The UV-Vis absorption spectra of
the corresponding pure compounds, TPP, 1-Ir and 4-Ir, exhibit
similar absorption bands in tetrahydrofuran (Fig. S20†). The
analogous Ir(III) complex alone possesses absorption bands
around 350–500 nm. Such a short absorption wavelength is not
suitable for practical clinical applications.63 The molar absorp-
tion coefficient at 650 nm follows the sequence 4-Ir NPs (3 ¼ 10
 4.12M1 cm1) > 1-IrNPs (3¼ 10 3.84M1 cm1) > TPPNPs
(3 ¼ 10  3.38 M1 cm1) consistent with efficient intra-
molecular energy transfer between the porphyrin and the Ir
centers. The simulated absorption spectra for TPP and 4-Ir in
the long-wavelength region by TDDFT/B3LYP methods
(Fig. S23†) also indicate that 4-Ir NPs possess stronger absorp-
tion than that of TPP NPs at 550 nm. The NPs all exhibited NIR
emission (Fig. 2D). The emission intensity of TPPNPs at 720 nm
is 1.84 and 7.14 times higher than 1-Ir NPs and 4-Ir NPs,
respectively. In addition, L4 and TPP exhibit similar photo-
physical properties (Fig. S21†). The increased molar absorbance
coefficient and the reduced emission intensity are conducive to
accelerating the transfer of excited energy to the triplet state and
to nonradiative vibrational processes, thereby improving the
efficiency of both PDT and PTT.64
The photoluminescence quantum yields (PLQYs) in water of
TPP NPs (29%) are higher than those of 1-Ir NPs and 4-Ir NPs
(11% and 5%, respectively) (Table S2†). The uorescent
quantum efficiency and kr values decrease from TPP NPs, 1-Ir
NPs to 4-Ir NPs, while knr gradually increases from TPP NPs, 1-Ir
NPs to 4-Ir NPs. 4-Ir NPs are more likely to promote highly
effective ISC which is benecial to efficient utilization of the
absorbed light energy for PDT and PTT. The excited-state life-
times (s) of TPP NPs (4.32 ns), 1-Ir NPs (4.67 ns) and 4-Ir NPs
(4.82 ns) are all at the nanosecond level (Table S2†), meaning
that the uorescence of 1-Ir NPs and 4-Ir NPs is from the
porphyrin unit and not from the phosphorescent Ir complexes.
Meanwhile, the s values gradually increase in the order TPP
NPs< 1-Ir NPs < 4-Ir NPs, which is more conducive to the
generation of a long-lived triplet photoexcited state from 4-Ir
NPs. This favors the full energy transfer between 4-Ir NPs and
oxygen molecules in the process of photodynamic therapy to
obtain high-efficiency singlet oxygen. Together with the
computational results, these experimental data demonstrate
that 4-Ir NPs fully achieve our molecular design objective of
iridium-porphyrin conjugate nanoparticles with long wave-
length excitation and near-infrared emission for synergistic
PDT and PTT treatment.
High 1O2 generation is a pre-requisite for efficient PDT.65,66
The 1O2 generation ability of TPP NPs, 1-Ir NPs and 4-Ir NPs was
monitored by using 1,3-diphenylisobenzofuran (DPBF) as an
indicator. Negligible spectral changes were observed in the
control groups: (i) DPBF + irradiation (635 nm, 0.4 W cm2, 90
s); (ii) PSs + irradiation; and (iii) DPBF + PSs, indicating excel-
lent photostability. As expected, upon irradiation, a continuous
and signicant decrease of absorbance was observed for solu-
tions of PSs and DPBF consistent with efficient 1O2 generation
(Fig. 2E and S23†). In contrast, the absorption spectra were
essentially unchanged with time for the following samples: (i)
DPBF + NPs (Fig. S25†); (ii) NPs + irradiation (Fig. S26†) and (iii)
DPBF + irradiation (Fig. S28†). The 1O2 generation of all the PSs
follows rst-order kinetics (Fig. 2F). The slopes are in the order
of TPP NPs (0.00637) < 1-Ir NPs (0.01859) < 4-Ir NPs (0.02654).
Notably, the slopes of 1-Ir NPs and 4-Ir NPs are 2.92 and 4.17
Fig. 2 (A) The synthesis of NPs; (B) stability of size distribution of
different PSs during 14 days, inset: the TEM images of (a) TPP NPs, (b)
1-Ir NPs and (c) 4-Ir NPs; (C), (D) UV-vis absorption and emission
spectra of PSs in water (1  105 M) inset: emission images of the PSs
under 365 nm UV illumination; (E) the decomposition rates of DPBF
(1.5  105 M) with different PSs (1  106 M) under irradiation
(635 nm, 0.4 W cm2); (F) time-dependent kinetics of 1O2 generation.
A0 ¼ absorption of DPBF without irradiation. A ¼ real-time absorption
of DPBF with different irradiation times.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 5918–5925 | 5921
































































































times higher than that of TPP NPs, respectively. The 1O2
quantum yields of TPP NPs, 1-Ir NPs and 4-Ir NPs are 54%, 72%
and 89%, respectively, with methylene blue (MB) as the refer-
ence (FD¼ 52% inMeCN). These results conrmed that the 4-Ir
NPs exhibit the highest 1O2 generation ability.
Subsequently, the photothermal activity of the NPs was
evaluated. Upon laser irradiation (635 nm, 0.8 W cm2, 300 s),
the aqueous solution temperatures of TPPNPs, 1-Ir NPs and 4-Ir
NPs (6  105 M) increased from room temperature to 43.3,
46.9 and 59.1 C, respectively, demonstrating photothermal
activity (Fig. 3A). In addition, the solution temperature of 4-Ir
NPs increased with the increasing concentration and the laser
power density (Fig. 3B and C). The photothermal conversion
efficiencies (h) of TPP NPs, 1-Ir NPs and 4-Ir NPs are 31.2%,
37.8% and 49.5%, respectively (Fig. S29†). These data clearly
indicate that the Ir centers signicantly improve the photo-
thermal effect. The data for 4-Ir NPs are shown in Fig. 3D–F,
including ve heating-cooling cycles which verify excellent
photothermal stability. The thermal images of TPP NPs, 1-Ir
NPs and 4-Ir NPs were observed upon 635 nm laser irradiation
for 10 min; the temperature of 4-Ir NPs (71.5 C) is higher than
that of 1-Ir NPs (60.3 C) and TPP NPs (47.4 C) (Fig. S30†).
Furthermore, both the absorbance and PL intensity of 4-Ir NPs
retain more than 90% of their initial values aer irradiation
with a 635 nm laser (0.8 W cm2, 5 min) for 7 days (Fig. S31†).
These results conrm that PSs based on a TPP-Ir(III) system
display prominent photothermal effects and excellent optical
stability.
The phototherapeutic efficacy of TPP NPs, 1-Ir NPs and 4-Ir
NPs was determined against HeLa cells by using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. In the dark, the cell viability exceeded 95% aer incu-
bation with TPP NPs, 1-Ir NPs and 4-Ir NPs, revealing good
cytocompatibility (Fig. 4A). In contrast, under laser irradiation
(635 nm, 0.6 W cm2, 5 min), TPP NPs, 1-Ir NPs and 4-Ir NPs
showed a concentration-dependent cytotoxicity (Fig. 4B). The
order of the half-maximal inhibitory concentration (IC50) is as
follows: TPP NPs (0.225 mM) > 1-Ir NPs (0.145 mM) > 4-Ir NPs
(0.057 mM). The lower IC50 value with 4-Ir NPs validates that
more Ir centers can enhance the therapeutic effect. A similar
effect was observed in HeLa cells aer incubation with 4-Ir NPs
for 72 h (Fig. S32†). Furthermore, the inhibition rate slightly
reduced with 62.2% in the presence of Vitamin C, while the
viability of cells decreased with 42.1% treated with a tempera-
ture of 4 C (Fig. 4C). These results indicated that 4-Ir NPs
possess synergetic PDT and PTT effects, and that the PDT effect
is dominant.
The intracellular ROS generation has also been investigated
by using 20,70-dichlorouorescin diacetate (DCFH-DA) as
a probe (Fig. 4D). Negligible green uorescence was detected in
the control groups indicating a lack of ROS generation: (i)
DCFH-DA only (control); (ii) DCFH-DA + 4-Ir NPs; (iii) DCFH-DA
+ 4-Ir NPs + Vitamin C; (iv) DCFH-DA + irradiation. However,
obvious green uorescence was monitored from the cells
cultured with 4-Ir NPs containing DCFH-DA under irradiation,
whereas green uorescence disappeared when the ROS capturer
Vitamin C was added, indicating the effective generation of ROS
in the cells. (Fig. S23†). Besides, bright eld images show that
the cells remain alive (Fig. S35†). The live/dead staining exper-
iments further visually investigated the therapeutic effect of 4-Ir
NPs in vitro (Fig. 4E). Upon laser irradiation, negligible green
Fig. 3 (A) Photothermal heating curves of water, TPP NPs, 1-Ir NPs
and 4-Ir NPs (6  105 M) in aqueous solution under irradiation
(635 nm, 0.8W cm2); (B) 4-IrNPs with different concentrations under
irradiation (635 nm, 0.8 W cm2); (C) 4-Ir NPs (6  105 M) with
different laser power densities; (D) photothermal effect of the 4-Ir NPs
(6 105 M) dispersions under irradiation (635 nm, 0.8W cm2), which
was turned off after irradiation for 300 s; (E) plot of cooling time versus
negative natural logarithm of the temperature obtained from the
cooling stage of the 4-IrNPs; (F) temperature variations of the 4-IrNPs
under irradiation (635 nm, 0.8 W cm2) for five light on/off cycles
(300 s of irradiation for each cycle).
Fig. 4 Cell viability of different PSs against HeLa cells. (A) in the dark
and (B) under light (L) (635 nm, 0.6 W cm2, 5 min); (C) cell viability of
4-IrNPs against HeLa cells under different conditions; VC¼ Vitamin C;
(D) generation of intracellular reactive oxygen species (ROS) mediated
by 4-Ir NPs (0.5 mM) upon irradiation (635 nm, 0.6 W cm2, 3 min) as
indicated by the fluorescence of DCFH-DA, the scale bars are 20 mm;
(E) fluorescence images of live cells (green) and dead cells (red) with 4-
IrNPs (0.5 mM) under irradiation (635 nm, 0.6 W cm2, 5 min), the scale
bars are 40 mm.
5922 | Chem. Sci., 2021, 12, 5918–5925 © 2021 The Author(s). Published by the Royal Society of Chemistry
































































































uorescence was observed, implying that almost all of the cells
were killed by 4-Ir NPs. In contrast, under the same conditions,
signicant green uorescence was monitored from the cells
treated at 4 C and with Vitamin C. Compared with the 4 C
treatment, the cells with Vitamin C exhibited brighter green
uorescence, proving the inhibition rate evidently decreased.
These results are in accordance with the MTT assay.
The intracellular uptake and distribution of TPP NPs, 1-Ir
NPs and 4-Ir NPs were evaluated in HeLa cells. Confocal laser
scanning microscopy (CLSM) showed that all the NPs exhibited
comparable intracellular red emission, suggesting that they can
be internalized by living cells (Fig. S33†). In addition, the rela-
tively weak red uorescence observed in HeLa cells treated with
sodium azide which causes energy depletion (Fig. S34†)
suggests that energy-mediated endocytosis is the primary
uptake pathway for the NPs. These results convincingly verify
the excellent biocompatibility and outstanding synergistic PDT
and PTT treatment effect of 4-Ir NPs.
Inspired by the in vitro performance, 4-Ir NPs were assessed
in vivo with U14 tumor-bearing mice. These murine models
were randomized into six groups: (1) with saline; (2) with saline
+ light; (3) 4-Ir NPs + IT; (4) 4-Ir NPs + IV; (5) 4-Ir NPs + IT + light,
(6) 4-Ir NPs + IV + light. As shown in Fig. S36,† the strong
uorescence intensity of U14 tumor-bearing mice aer intra-
venous (IV) injection with IR780-labeled 4-Ir NPs into the tumor
gradually increased within 12 h (with negligible residues in
surrounding tissues) showing rapid and high accumulation of
4-Ir NPs. These data indicated that 12 h aer injection is the
optimal time for light irradiation. An infrared thermal camera
was used to monitor the temperature changes at the tumor
sites. As illustrated in Fig. 5A and C, the temperature reached
a plateau of 61.9 C and 53.0 C with intratumoral (IT) and
intravenous injection aer 10 min irradiation, respectively,
manifesting the superior photothermal imaging and treatment
effect. The tumor volume increased swily during two weeks in
groups 1 to 4 (Fig. 5D), demonstrating that neither laser irra-
diation alone, nor 4-Ir NPs alone, could suppress tumor growth.
In sharp contrast, markedly reduced tumor volume and weight
was observed in both groups 5 and 6 (Fig. 5B and F), indicating
the outstanding tumor inhibition efficiency of 4-Ir NPs under
irradiation. The white spot in Fig. 5B indicates that the tumor
tissue had been completely killed. For the tumors in groups 5
and 6, 4-Ir NPs had a highly efficient tumor inhibition rate
exceeding 90% (Fig. S37†). This can be attributed to the
enhanced permeability and retention (EPR) effect of 4-Ir NPs for
systematically enhanced tumor targeting. There was no
abnormal murine body weight loss in groups 2 to 6 (Fig. 5E),
validating the minimal systemic toxicity of 4-Ir NPs.
To study further the biodistribution of 4-Ir NPs, the ex vivo
uorescence images of the major organs and tumor were ob-
tained (Fig. S38 and S39†). The strongest uorescence intensity
was observed from tumor, liver and kidney. H&E-stained images
of heart, liver, spleen, lung, kidney and tumor from sacriced
mice in each group were collected and assessed. No noticeable
abnormalities in major organs from the six treatment groups
were discovered, implying that 4-Ir NPs are harmless in vivo.
However, the tumor slices from groups 5 and 6 exhibit obvious
cellular nuclei damage, suggesting that 4-Ir NPs caused cell
apoptosis and necrosis. All these results indicated that 4-Ir NPs
are eminently suitable for phototherapy in vivo.
Conclusions
In summary, this work has demonstrated that iridium–
porphyrin conjugates encapsulated in nanoparticles can act as
PSs for photothermal imaging-guided synergistic PDT and PTT
therapy. Two deep-red absorbing, NIR-emitting compounds
were rationally designed and synthesized. The small DEST,
separation of HOMO–LUMO, abundant and effective photoex-
cited state and high spin–orbit coupling constant increases with
the number of peripheral Ir centers, thereby increasing the
molar absorption coefficient at long wavelengths (635 nm), 1O2
production capacity and photothermal activity. Especially, 4-Ir
NPs are ideal PSs for cancer treatment because of the following
advantages: deep-red absorption, long-wavelength excitation
(635 nm), NIR emission, remarkable 1O2 generation ability,
excellent photothermal conversion efficiency (49.5%), negli-
gible dark toxicity and low IC50 (0.057 mM). Furthermore, both
intravenous and intratumoral injections of 4-Ir NPs exhibited
an obvious temperature rise and high-efficiency inhibitory
effect for tumor growth in vivo. This study provides new insights
in the design of multifunctional PSs with long excitation
wavelength for clinical therapeutic applications.
Fig. 5 (A) Photothermal imaging of mice treated with 4-IrNPs (100 mg
mL1, 100 mL) under 635 nm laser irradiation at intensity 360 J cm2 for
10 min; (B) harvested tumors from various groups of mice after
treatment; (C) temperature of tumors monitored by the infrared
thermal camera in different groups upon laser irradiation; (D) tumor
volume measurement for different groups of mice; (E) body weights
for different groups of mice; (F) tumor weights of six groups, repre-
senting the total weight of four samples in each group.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 5918–5925 | 5923
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